Fulvestrant: beside a new treatment under test
271 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 3. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2Report a problem
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTerminatedNCT05384119Phase 1Results postedReport a problem
- A Study of Lerociclib in Participants With Advanced Breast CancerTerminatedNCT05085002Phase 2Results postedReport a problem
- A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor CancerCompletedNCT05054374Phase 1/2Results postedReport a problem
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)TerminatedNCT04738292Phase 2Results postedReport a problem
- Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorActive, not recruitingNCT04650581Phase 3Results postedReport a problem
- Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04305496Phase 3Results postedReport a problem
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results postedReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT04191499Phase 2/3Results postedReport a problem
- A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerTerminatedNCT04060862Phase 1Results postedReport a problem
- A Study of TAS-120 in Patients With Metastatic Breast CancerTerminatedNCT04024436Phase 2Results postedReport a problem
- MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results postedReport a problem
- Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results postedReport a problem
- Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced MalignanciesCompletedNCT03363893Phase 1/2Results postedReport a problem
- A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast CancerCompletedNCT03344536Phase 1/2Results postedReport a problem
- MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results postedReport a problem
- Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerTerminatedNCT03241810Phase 2Results postedReport a problem
- Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results postedReport a problem
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerCompletedNCT03179904Phase 2Results postedReport a problem
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedNCT03099174Phase 1Results postedReport a problem
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsCompletedNCT03056755Phase 2Results postedReport a problem
- GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerTerminatedNCT02983604Phase 1/2Results postedReport a problem
- Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast CancerTerminatedNCT02964507Phase 1Results postedReport a problem
- Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerCompletedNCT02860000Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results postedReport a problem
- Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)TerminatedNCT02761694Phase 1Results postedReport a problem
- Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyCompletedNCT02756364Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results postedReport a problem
- An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results postedReport a problem
- Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseCompletedNCT02640755Phase 1Results postedReport a problem
- Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast CancerCompletedNCT02632045Phase 2Results postedReport a problem
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedNCT02437318Phase 3Results postedReport a problem
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results postedReport a problem
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerCompletedNCT02392611Phase 1Results postedReport a problem
- Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With FulvestrantTerminatedNCT02374099Phase 2Results postedReport a problem
- A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyTerminatedNCT02340221Phase 3Results postedReport a problem
- An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary ObjectiveCompletedNCT02116803Phase 2/3Results postedReport a problem
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingNCT02107703Phase 3Results postedReport a problem
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedNCT02049957Phase 2Results postedReport a problem
- Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsTerminatedNCT01953926Phase 2Results postedReport a problem
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)CompletedNCT01942135Phase 3Results postedReport a problem
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedNCT01670877Phase 2Results postedReport a problem
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiTerminatedNCT01633060Phase 3Results postedReport a problem
- Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorCompletedNCT01610284Phase 3Results postedReport a problem
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedNCT01597388Phase 1Results postedReport a problem
- Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerCompletedNCT01597193Phase 1Results postedReport a problem
- Fulvestrant With or Without Ganetespib in HR+ Breast CancerCompletedNCT01560416Phase 2Results postedReport a problem
- Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast CancerTerminatedNCT01528345Phase 2Results postedReport a problem
- Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast CancerCompletedNCT01441947Phase 2Results postedReport a problem
- A Phase 1 Study of LY2835219 In Participants With Advanced CancerCompletedNCT01394016Phase 1Results postedReport a problem
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerTerminatedNCT01296555Phase 1Results postedReport a problem
- Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsCompletedNCT01202591Phase 1/2Results postedReport a problem
- Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast CancerTerminatedNCT00903006Phase 1/2Results postedReport a problem
- ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex TrialTerminatedNCT00752986Phase 2Results postedReport a problem
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCompletedNCT00728949Phase 2Results postedReport a problem
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00626106Phase 2Results postedReport a problem
- Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureCompletedNCT00570921Phase 2Results postedReport a problem
- AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.CompletedNCT00454805Phase 2Results postedReport a problem
- Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast CancerCompletedNCT00451555Phase 2Results postedReport a problem
- Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveCompletedNCT00390455Phase 3Results postedReport a problem
- Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerTerminatedNCT00372996Phase 2Results postedReport a problem
- Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT00082810Phase 2Results postedReport a problem
- Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsWithdrawnNCT07570966Phase 1/2Report a problem
- A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.Active, not recruitingNCT07557004Phase 1Report a problem
- Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerTerminatedNCT07408089Phase 1Report a problem
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsActive, not recruitingNCT07038369Phase 1Report a problem
- Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerTerminatedNCT06851442Phase 1/2Report a problem
- Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerActive, not recruitingNCT06702618Phase 2Report a problem
- PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerActive, not recruitingNCT06612814Phase 3Report a problem
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerActive, not recruitingNCT06447623Phase 3Report a problem
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1Report a problem
- BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsCompletedNCT06253195Phase 1Report a problem
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingNCT06239467Phase 1Report a problem
- Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.Status unknownNCT06133088Phase 2Report a problem
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingNCT06105632Phase 2Report a problem
- Phase I Study of BEBT-209 in Women With Advanced Breast CancerCompletedNCT06047184Phase 1Report a problem
- A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsCompletedNCT05963984Phase 2Report a problem
- Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerTerminatedNCT05932667Phase 2Report a problem
- Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.WithdrawnNCT05905341Phase 1Report a problem
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1Report a problem
- Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast CancerStatus unknownNCT05808582Phase 2Report a problem
- Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant TherapyStatus unknownNCT05806047Phase 2Report a problem
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsCompletedNCT05759949Phase 1Report a problem
- Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerActive, not recruitingNCT05759572Phase 2Report a problem
- Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2Report a problem
- Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruitingNCT05546268Phase 1/2Report a problem
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingNCT05501886Phase 3Report a problem
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownNCT05438810Phase 3Report a problem
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerActive, not recruitingNCT05433480Phase 3Report a problem
- Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.Status unknownNCT05411380Phase 2Report a problem
- TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailCompletedNCT05375461Phase 3Report a problem
- To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Phase 3Report a problem
- Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)Active, not recruitingNCT05328440Phase 2Report a problem
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1Report a problem
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsActive, not recruitingNCT05262400Phase 1/2Report a problem
- (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1Report a problem
- CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerActive, not recruitingNCT05251714Phase 1/2Report a problem
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1Report a problem
- Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsStatus unknownNCT05191914Phase 4Report a problem
- Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCWithdrawnNCT05191004Phase 1/2Report a problem